REZOLUTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.97 USD | +7.61% |
|
+14.23% | +199.24% |
| 04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| 03-06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Chart calendar Rezolute, Inc.
ee53b4ebd9c1387.Dh61msHA6SlPoGe0O_he46n7dW_gms390foR8gxHph4.Om3y_PSFh0onjVP6YY4Qpt-oRya00pikoZl5qlUIlk48ZOXwirOaYQXFIg~bfffa77af2102b7a1a4b06f4b4dda646
Upcoming events on Rezolute, Inc.
Past events on Rezolute, Inc.
| 13/02/2024 21:05 | Q2 2024 Earnings Release |
| 27/11/2023 19:30 | BTIG Ophthalmology Day |
| 13/11/2023 21:05 | Q1 2024 Earnings Release |
| 26/09/2023 19:10 | Cantor Global Healthcare Conference |
| 14/09/2023 21:05 | Q4 2023 Earnings Release |
| 12/09/2023 19:00 | H.C. Wainwright Global Investment Conference |
| 27/06/2023 21:30 | RZ358 Phase3 Update Call |
| 25/05/2023 23:00 | Annual General Meeting |
| 11/05/2023 21:05 | Q3 2023 Earnings Release |
| 22/03/2023 20:30 | Investor Meeting - Key Opinion Leader |
| 10/02/2023 21:05 | Q2 2023 Earnings Release |
| 17/11/2022 16:25 | Jefferies London Healthcare Conference |
| 09/11/2022 21:05 | Q1 2023 Earnings Release |
| 03/11/2022 17:47 | Retina Society Scientific Meeting |
| 15/09/2022 21:05 | FY 2022 Earnings Release |
| 15/09/2022 13:55 | European Society for Paediatric Endocrinology Conference - Abstract Code FC3.2 |
| 16/06/2022 23:00 | Annual General Meeting |
| 12/05/2022 21:05 | Q3 2022 Earnings Release |
| 04/05/2022 21:30 | Business Update Call |
| 01/05/2022 19:30 | RZ358 Phase 2b Study Results Call |
Annual results
| Fiscal Period | June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -25,9 -31,3 17.11% | 0,00 0,00 - | -22,9 -22,5 -1.68% | -41,8 -45,1 7.27% | -56,0 -60,0 6.65% | -65,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -30,4 -35,8 14.96% | 0,00 0,00 - | -20,9 -22,1 5.26% | -41,1 -46,7 12.08% | -51,8 -58,0 10.74% | -61,8 |
|
Net income Million USD | Released Forecast Spread | -30,4 -35,8 14.96% | -20,3 -21,8 6.73% | -20,9 -21,6 3.15% | -41,1 -46,7 12.08% | -51,8 -57,8 10.46% | -61,0 |
|
EPS USD | Released Forecast Spread | -18,5 -15,0 -23.33% | -3,54 -4,00 11.5% | -2,72 -2,82 3.63% | -2,26 -2,48 8.99% | -1,01 -1,22 17.35% | -1,12 |
| Announcement Date | 10/09/19 | 13/10/20 | 15/09/21 | 15/09/22 | 14/09/23 | - |
Quarterly results
| Fiscal Period | June | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -12,1 -8,67 -40.21% | -10,8 -15,5 30.66% | -11,3 -14,6 22.58% | -10,2 -12,2 16.06% | -14,4 -15,5 7.41% | -17,1 -15,7 -8.84% | -14,2 -18,2 21.82% | -15,9 -16,5 3.52% | -15,2 -18,1 15.94% | -16,4 | -17,4 | -18,0 | -19,2 | -20,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -12,6 -8,98 -40.31% | -11,2 -16,2 30.67% | -9,42 -15,1 37.5% | -9,83 -12,4 20.86% | -13,6 -13,5 -0.27% | -15,7 -15,6 -0.51% | -12,7 -18,5 31.21% | -14,5 -16,4 11.25% | -13,9 -16,7 16.57% | -15,9 | -16,4 | -18,0 | -19,2 | -20,4 |
|
Net income Million USD | Released Forecast Spread | -12,6 -8,93 -41% | -11,2 -15,9 29.62% | -9,42 -15,1 37.5% | -9,83 -12,4 20.86% | -13,6 -13,5 -0.27% | -15,7 -15,6 -0.51% | -12,7 -18,5 31.21% | -14,5 -13,5 -7.86% | -13,9 -16,9 17.58% | -15,9 | -16,4 | -18,0 | -19,2 | -20,4 |
|
EPS USD | Released Forecast Spread | -0,80 -0,69 -16.28% | -0,65 -0,91 28.26% | -0,30 -0,56 45.95% | -0,19 -0,31 39.36% | -0,26 -0,32 18.24% | -0,30 -0,30 0% | -0,25 -0,36 29.78% | -0,28 -0,28 0.88% | -0,27 -0,29 6.9% | -0,30 | -0,28 | -0,32 | -0,32 | -0,29 |
| Announcement Date | 09/02/22 | 12/05/22 | 15/09/22 | 09/11/22 | 10/02/23 | 11/05/23 | 14/09/23 | 13/11/23 | 13/02/24 | - | - | - | - | - |
More events
Past sector events for Rezolute, Inc.
| 02/05/2024 21:01 | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 02/05/2024 16:00 | GENMAB A/S: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:30 | SPRINGWORKS THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:30 | REGENERON PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:00 | AURINIA PHARMACEUTICALS INC.: Q1 2024 Earnings Release |
| 01/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 | KURA ONCOLOGY, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RZLT Stock
- Calendar Rezolute, Inc.
